PRECIGEN, INC. Public Float
PRECIGEN, INC. (PGEN) had Public Float of $219.40 million as of 2025-06-30, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-03-25
- 2025-06-30: Entity Public Float $219.40M.
- 2024-06-30: Entity Public Float $239.80M.
- 2023-06-30: Entity Public Float $177.30M.
- 2022-06-30: Entity Public Float $162.10M.
| Period end | Entity Public Float |
|---|---|
| 2025-06-30 | $219.40M 10-K · filed 2026-03-25 |
| 2024-06-30 | $239.80M 10-K/A · filed 2025-04-28 |
| 2023-06-30 | $177.30M 10-K/A · filed 2024-04-29 |
| 2022-06-30 | $162.10M 10-K · filed 2023-03-06 |
| 2021-06-30 | $790.40M 10-K · filed 2022-03-01 |
| 2020-06-30 | $435.10M 10-K · filed 2021-03-01 |
| 2019-06-28 | $659.70M 10-K · filed 2020-03-02 |
| 2018-06-30 | $959.40M 10-K · filed 2019-03-01 |
| 2017-06-30 | $1.40B 10-K · filed 2018-03-01 |
| 2016-06-30 | $1.40B 10-K · filed 2017-03-01 |
| 2015-06-30 | $2.30B 10-K · filed 2016-02-29 |
| 2014-06-30 | $902.20M 10-K · filed 2015-03-02 |
| 2013-12-31 | $814.40M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |